l glutathione and fatty liver What is why must we protect patient access to it? Frontiers | Glutathione: Pharmacological aspects
Description
M.BargaineerJ.ZhangL.YangT.XiongZ
doi: 10.1016/j.ijbiomac.2012.11.023, 16
Rothman, D
Both ligands were first optimised by B3LYP/6-31 G* 42 in Gaussian 09 43 and the optimised structure was used for calculating point charges and force constants
